NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website


MIRAMAR, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has launched its new corporate website to provide investors with information on the NGIO mission, management, and pipeline for the Ii-Key vaccine platform for cancer and infectious disease. You can also learn about the company’s ongoing SARS-CoV-2 vaccine development program and collaborations. You can visit the site at https://www.nugenerexio.com/.

Read more from the original source:
NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website

Related Posts